佛慈制药(002644) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥177,434,087.22, representing a 28.61% increase compared to ¥137,964,409.24 in the same period last year[8]. - Net profit attributable to shareholders was ¥23,105,239.34, an increase of 87.63% from ¥12,314,230.92 year-on-year[8]. - Basic earnings per share rose to ¥0.0452, a 73.36% increase compared to ¥0.0261 in the same period last year[8]. - Net profit for Q1 2021 was ¥23,102,526.78, up from ¥12,238,296.64 in the same period last year, representing an increase of approximately 89.0%[41]. - The company's operating revenue for the current period is ¥142,145,866.81, an increase from ¥98,732,914.87 in the previous period, representing a growth of approximately 43.8%[44]. - The net profit for the current period is ¥24,591,109.52, compared to ¥10,932,009.61 in the previous period, indicating a significant increase of about 125.5%[45]. - The operating profit for the current period is ¥28,909,580.66, up from ¥13,046,073.60 in the previous period, reflecting an increase of approximately 121.5%[46]. Cash Flow - The net cash flow from operating activities reached ¥29,491,155.97, up 112.38% from ¥13,886,124.13 in the previous year[8]. - The net cash flow from operating activities increased by 112.38% to ¥29,491,155.97 compared to the previous year, primarily due to reduced cash payments for purchases and services[17]. - The net cash flow from investing activities decreased by 161.67% to -¥47,277,799.97, mainly due to increased investment expenditures from purchasing short-term financial products[18]. - The net cash flow from financing activities decreased by 285.52% to -¥20,315,380.81, attributed to a reduction in cash received from borrowings compared to the previous year[18]. - The company reported a total operating cash inflow of ¥189,824,807.94, compared to ¥178,208,912.98 in the previous period, an increase of about 6.5%[47]. - The total operating cash outflow for the current period is ¥160,333,651.97, slightly down from ¥164,322,788.85 in the previous period, a decrease of about 2.0%[49]. - The total cash and cash equivalents at the end of the period is ¥381,859,384.39, down from ¥425,205,240.58 in the previous period, a decrease of approximately 10.2%[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,419,600,456.04, reflecting a 6.73% increase from ¥2,267,132,508.63 at the end of the previous year[8]. - The total liabilities increased to ¥806,098,570.01 from ¥670,964,161.33, reflecting a rise in both current and non-current liabilities[32]. - The company's cash and cash equivalents decreased to ¥381,859,384.39 from ¥419,961,409.20, indicating a reduction in liquidity[30]. - Current liabilities totaled ¥401,452,337.77, an increase from ¥324,841,218.46, which is a rise of approximately 23.5%[37]. - The total liabilities of the company as of March 31, 2021, were ¥760,500,483.55, up from ¥656,078,767.30, indicating an increase of about 15.9%[37]. Shareholder Information - The total number of shareholders at the end of the reporting period was 32,715[11]. - The company's retained earnings increased to ¥655,061,776.28 from ¥640,020,346.51, reflecting ongoing profitability[33]. Compliance and Standards - The company reported no significant non-compliance issues or overdue commitments during the reporting period[19]. - The company did not undergo an audit for the first quarter report[55]. - The company did not apply the new leasing standards for the first quarter of 2021[54]. Other Financial Metrics - The company received government subsidies amounting to ¥17,042,969.46 during the reporting period[9]. - The company incurred research and development expenses of ¥3,021,963.41, a decrease from ¥6,409,579.19 in the previous period, representing a reduction of approximately 52.9%[44]. - The company reported other income of ¥16,984,589.46, compared to ¥5,694,652.73 in the previous period, indicating an increase of about 198.5%[44]. - The company's financial expenses show a net income of -¥3,037,732.43, compared to -¥3,438,459.53 in the previous period, reflecting an improvement of approximately 11.7%[44].